"To the best of our knowledge, there have been no reports of urinary biomarkers being used to evaluate COVID-19 disease activity, rather than evaluating the renal function of COVID-19 patients," says Katagiri, Daisuke MD, PhD and colleagues. "Our findings suggest that urinary biomarkers, especially β2MG and L-FABP, may assist with predicting severity at an early stage."
|